← Back to Search

Protein Therapeutics

Luspatercept for Myelodysplastic Syndrome-related Anemia

Phase 2
Recruiting
Led By Rami Komrokji, MD
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up end of treatment, up to 18 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if luspatercept can reduce the need for blood transfusions in participants with anemia caused by MDS or MDS/MPN. It will also assess the safety and tolerability of luspatercept.

Who is the study for?
This trial is for adults with certain types of bone marrow disorders (MDS or MDS/MPN) that cause anemia and require regular blood transfusions. Participants must have specific genetic mutations, not be pregnant or breastfeeding, and cannot have severe kidney issues or other active cancers. They should not have had prior stem cell transplants and must agree to contraception if applicable.
What is being tested?
The study tests whether Luspatercept plus supportive care reduces the need for blood transfusions in patients with anemia due to MDS or MDS/MPN. It also assesses the safety and side effects of Luspatercept in these patients.
What are the potential side effects?
While the specific side effects are not listed here, generally such treatments may include risks like fatigue, injection site reactions, muscle aches, headaches, nausea, high blood pressure, dizziness and potential risk of developing new or worsening tumors.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~end of treatment, up to 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and end of treatment, up to 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
RBC Transfusion Independence
Secondary study objectives
ASC specks changes with response
Duration of Response
Hematological Improvement
+1 more

Side effects data

From 2021 Phase 3 trial • 336 Patients • NCT02604433
42%
Upper respiratory tract infection
35%
Headache
32%
Back pain
23%
Arthralgia
22%
Bone pain
22%
Cough
21%
Pyrexia
18%
Oropharyngeal pain
18%
Diarrhoea
17%
Fatigue
16%
Pharyngitis
15%
Pain in extremity
13%
Abdominal pain
13%
Nausea
13%
Vomiting
13%
Myalgia
13%
Dizziness
12%
Asthenia
11%
Abdominal pain upper
11%
Influenza
10%
Hypertension
9%
Dyspepsia
9%
Influenza like illness
9%
Musculoskeletal pain
9%
Nasal congestion
8%
Nasopharyngitis
8%
Gastroenteritis
8%
Urticaria
7%
Toothache
7%
Tonsillitis
7%
Hyperuricaemia
6%
Pain
6%
Urinary tract infection
6%
Viral upper respiratory tract infection
6%
Neck pain
6%
Osteoporosis
5%
Constipation
5%
Injection site pain
5%
Transfusion reaction
5%
Alanine aminotransferase increased
5%
Spinal pain
5%
Lethargy
5%
Menstruation irregular
5%
Liver iron concentration increased
4%
Fall
4%
Musculoskeletal chest pain
2%
Anaemia
1%
Septic shock
1%
Extramedullary haemopoiesis
1%
Deep vein thrombosis
1%
Transient ischaemic attack
1%
Cerebrovascular accident
1%
Cholangitis
1%
Cholecystitis acute
1%
Cellulitis
1%
Pneumonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Luspatercept + BSC
Placebo + BSC

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Participants with gene mutations other than SF3B1Experimental Treatment1 Intervention
Participants with lower risk MDS or non-proliferative MDS/MPN with somatic splicing gene mutations other than SF3B1
Group II: Participants with SF3B1 mutationExperimental Treatment1 Intervention
Participants with lower risk MDS or non-proliferative MDS/MPN with SF3B1 mutation who had received hypomethylating agents and or lenalidomide.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Luspatercept
2018
Completed Phase 3
~1240

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
561 Previous Clinical Trials
144,759 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,682 Previous Clinical Trials
4,124,951 Total Patients Enrolled
Rami Komrokji, MDPrincipal InvestigatorMoffitt Cancer Center
5 Previous Clinical Trials
225 Total Patients Enrolled

Media Library

Luspatercept (Protein Therapeutics) Clinical Trial Eligibility Overview. Trial Name: NCT05732961 — Phase 2
Myelodysplastic Syndrome Research Study Groups: Participants with gene mutations other than SF3B1, Participants with SF3B1 mutation
Myelodysplastic Syndrome Clinical Trial 2023: Luspatercept Highlights & Side Effects. Trial Name: NCT05732961 — Phase 2
Luspatercept (Protein Therapeutics) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05732961 — Phase 2
~13 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top